{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:49:27Z","timestamp":1777614567406,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Pediatric Neurology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.spen.2023.101036","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T22:08:50Z","timestamp":1677103730000},"page":"101036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The White Coat Cape: An Ethical Analysis of Emerging Therapies to Treat Spinal Muscular Atrophy"],"prefix":"10.1016","volume":"45","author":[{"given":"Jane A.","family":"Hartsock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.spen.2023.101036_bib0001","series-title":"Stories Matter: The Role of Narrative in Medical Ethics","first-page":"97","article-title":"The narrative of rescue in pediatric practice","author":"Robinson","year":"2002"},{"issue":"5","key":"10.1016\/j.spen.2023.101036_bib0002","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11910-017-0749-7","article-title":"Reflections on ethics and humanity in pediatric neurology: The value of recognizing ethical issues in common clinical practice","volume":"17","author":"Ronen","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.spen.2023.101036_bib0003","unstructured":"U.S. Food & Drug Administration. FDA approves new breakthrough therapy for cystic fibrosis,https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-breakthrough-therapy-cystic-fibrosis#:~:text=Trikafta%20is%20the%20first%20approved,people%20in%20the%20United%20States; 2019 [Accessed October 10, 2022]."},{"issue":"7S","key":"10.1016\/j.spen.2023.101036_bib0004","doi-asserted-by":"crossref","first-page":"7S50","DOI":"10.1016\/S0929-693X(20)30278-5","article-title":"Ethical aspects in the care of a child with infantile spinal muscular atrophy (SMA)","volume":"27","author":"Chabrol","year":"2020","journal-title":"Arch Pediatr"},{"issue":"4","key":"10.1016\/j.spen.2023.101036_bib0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.arcped.2021.02.004","article-title":"New ethical challenges in the management of rare pediatric diseases with innovative therapies","volume":"28","author":"Dufosset","year":"2021","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.spen.2023.101036_bib0006","series-title":"The View From Nowhere","first-page":"208","article-title":"Birth, death, and the meaning of life","author":"Nagel","year":"1986"},{"issue":"3","key":"10.1016\/j.spen.2023.101036_bib0007","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bcp.13833","article-title":"Ethics codes and use of new and innovative drugs","volume":"85","author":"Borysowski","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.spen.2023.101036_bib0008","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/adc.2008.155317","article-title":"Compassionate and innovative treatments in children: A proposal for an ethical framework","volume":"94","author":"Brierley","year":"2009","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.spen.2023.101036_bib0009","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bioe.12381","article-title":"Medical innovation in a children's hospital: \u2018Diseases desperate grown by desperate appliance are relieved, or not at all.\u2019","volume":"32","author":"v","year":"2018","journal-title":"Bioethics"},{"issue":"10","key":"10.1016\/j.spen.2023.101036_bib0010","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/jp.2012.69","article-title":"Ethics of emerging technologies and their transition to accepted practice: Intestinal transplant for short bowel syndrome","volume":"32","author":"Cummings","year":"2012","journal-title":"J Perinatol"},{"key":"10.1016\/j.spen.2023.101036_bib0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.spen.2023.101036_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107719","article-title":"Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy","volume":"220","author":"Iftikhar","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.spen.2023.101036_bib0013","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pediatrneurol.2021.09.011","article-title":"Gene-targeted therapies in pediatric neurology: Challenges and opportunities in diagnosis and delivery","volume":"125","author":"Shellhaas","year":"2021","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.spen.2023.101036_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.750742","article-title":"Assessing the value of Nusinersen for spinal muscular atrophy: A comparative analysis of reimbursement submission and appraisal in European countries","volume":"12","author":"Blonda","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.spen.2023.101036_bib0015","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-022-11319-0","article-title":"Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia","author":"Wang","year":"2022","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.spen.2023.101036_bib0016","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.spen.2004.03.012","article-title":"Ethical issues in pediatric critical care neurology","volume":"11","author":"Shevell","year":"2004","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.spen.2023.101036_bib0017","series-title":"The Science of Right","author":"Kant","year":"2015"}],"container-title":["Seminars in Pediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909123000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909123000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:40:25Z","timestamp":1761028825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071909123000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":17,"alternative-id":["S1071909123000050"],"URL":"https:\/\/doi.org\/10.1016\/j.spen.2023.101036","relation":{},"ISSN":["1071-9091"],"issn-type":[{"value":"1071-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The White Coat Cape: An Ethical Analysis of Emerging Therapies to Treat Spinal Muscular Atrophy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Pediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spen.2023.101036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101036"}}